KW-2170 not sufficiently active for use in men with CRPC

KW-2170 is a drug that had been undergoing early clinical trials in Australia for the treatment of men with castration-resistant prostate cancer (CRPC).

A total of 44 men with CRPC were recruited for a multicenter, open label, non-randomized Phase II study, after earlier testing had shown that KW-2170 held promise for the treatment of men with advanced prostate cancer (see De Souza et al.).

Of these 44 patients, 35 were evaluable for PSA response to treatment with KW-2170, but only 5/35 patients demonstrated a fall in their PSA level of 50 percent or more. Median survival was these 35 evaluable patients was 18.9 months (compared to 16 months for the entire cohort of 44 patients).

Although KW-2170 appears to have been well tolerated, the low level of PSA response did not meet pre-specified criteria for further studies in men with prostate cancer.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: